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Background/Aims: Sarcopenia is associated with liver fi-
brosis in patients with nonalcoholic fatty liver disease and 
chronic hepatitis B. We investigated the association between 
sarcopenia and hepatic fibrotic burden in patients with type 
2 diabetes mellitus (T2DM). Methods: Patients with T2DM 
who had received a comprehensive medical health check-
up were recruited. Muscle mass was assessed using com-
puted tomography. Fibrotic burden was assessed using the 
fibrosis-4 index (FIB-4). The study population was divided by 
quartile stratification of the lumbar skeletal muscle index 
(LSMI). Results: Among 309 patients with T2DM, 75 (24.3%) 
had sarcopenia. These patients were significantly older and 
had higher FIB-4, whereas they had significantly lower body 
mass index (BMI) and LSMI than patients without sarcopenia 
(all p<0.05). The LSMI showed a significant negative cor-
relation with the FIB-4 when analyzed in terms of quartile 
stratification (p=0.003). Multivariate analysis showed that 
female sex and higher BMI were independently associated 
with a reduced risk of sarcopenia (odds ratio [OR], 0.388; 
95% confidence interval [CI], 0.199 to 0.755 and OR, 0.704; 
95% CI, 0.618 to 0.801; all p<0.05), whereas a higher FIB-
4 was independently associated with an increased risk of 
sarcopenia (OR, 1.817; 95% CI, 1.180 to 2.797; p=0.007). 
Among patients with a BMI <25 kg/m2 (n=165), those with 
sarcopenia (n=54, 32.7%) had a significantly higher FIB-4 
than those without (n=111, 67.3%; 1.66 vs 1.38, p=0.004). 
Conclusions: Sarcopenia is independently associated with 
fibrotic burden in patients with T2DM. Further studies should 
investigate whether the improvement of sarcopenia can 
ameliorate liver fibrosis in patients with T2DM. (Gut Liver 
2020;14:626-635)
Key Words: Sarcopenia; Liver fibrosis; Muscular atrophy; Dia-
betes mellitus; Fibrosis-4 index
INTRODUCTION
Sarcopenia is characterized by progressive and generalized 
loss of skeletal muscle mass and strength, with a risk of adverse 
outcomes, such as physical disability, poor quality of life, and 
death, according to the 2010 European Working Group on Sar-
copenia in Older People.1 In fact, sarcopenia has emerged as one 
of the most common problems in the elderly population, and 
it is one of the most significant public health concerns.2 Thus, 
the European Working Group on Sarcopenia in Older People 
emphasized that clinicians must measure and evaluate muscle 
mass, muscle strength, and physical performance to diagnose 
sarcopenia.1
Low skeletal muscle mass can be evaluated using various 
imaging techniques, such as dual-energy X-ray absorptiometry 
(DXA), computed tomography (CT), magnetic resonance imag-
ing, and bioimpedance analysis (BIA). Among these methods, 
CT images allow accurate quantitative and qualitative measure-
ment of body composition, including adipose tissue.1 Addition-
ally, skeletal muscle mass measured by CT, rather than BIA, is 
significantly correlated with muscle strength and physical per-
formance.3
Sarcopenia is often combined with various comorbidities,4 in-
cluding several cardiometabolic disorders such as diabetes mel-
litus, metabolic syndrome, cardiovascular disease, and nonalco-
holic fatty liver disease (NAFLD),5-8 which has become a major 
liver disease world-wide.9 Several recent studies have reported 
that sarcopenia is significantly associated with an increased risk 
of significant liver fibrosis in subjects with NAFLD.10-13 In addi-
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tion, in patients with chronic hepatitis B who have metabolical-
ly unhealthy features, sarcopenia is significantly associated with 
an increased risk of significant liver fibrosis similar to NAFLD.14 
However, few studies have addressed the relationship between 
sarcopenia and liver fibrosis in patients with type 2 diabetes 
mellitus (T2DM).
Thus, the aim of the present study was to compare clinical 
characteristics between patients with and without sarcopenia, as 
assessed using CT, as well as to investigate whether sarcopenia 




Between June 2010 and April 2018, we recruited 1,191 sub-
jects who had visited Severance Executive Healthcare Clinic in 
Severance Hospital, a university-affiliated tertiary care hospital, 
for a comprehensive medical health check-up over a 2-day hos-
pitalization period (Fig. 1). Of these, 868 were excluded because 
they had no available CT scan or did not have T2DM.15 Fourteen 
more were then excluded based on our exclusion criteria. Ulti-
mately, 309 patients with T2DM (215 men and 94 women) were 
selected for the statistical analysis. 
The protocol of the present study adhered to the tenets of the 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Severance Hospital (IRB number: 4-2018-
0856). The requirement for informed consent was waived be-
cause the study was retrospective.
2. Measurements of skeletal muscle area 
Skeletal muscle area was measured at the level of the L3 ver-
tebra, with the patients in the supine position, using either a du-
al-source, 128-slice CT scanner (Somatom Definition Flash; Sie-
mens Healthcare, Forchheim, Germany), a 64-slice CT scanner 
(Somatom Sensation 64; Siemens Healthcare), a 128 slice Dis-
covery 710 PET-CT scanner (General Electric Medical Systems, 
Milwaukee, WI, USA), a 40 slice Biograph TruePoint 40 PET-CT 
scanner (Siemens Medical Solutions, Hoffman Estates, IL, USA), 
or a 16 slice Discovery 600 PET-CT scanner (General Electric 
Medical Systems). The muscle area was identified as having at-
tenuation values between –29 and 150 Hounsfield units, and 
the total lumbar skeletal muscle area (psoas, erector spinae, qua-
dratus lumborum, transversus abdominus, external and internal 
obliques, and rectus abdominus), measured in cm2, was defined 
as the region with density ranging from –29 to –150 Hounsfield 
units, as measured using Aquarius Intuition Viewer software, 
version 4.4.12 (Terarecon, San Mateo, CA, USA). Boundaries 
were corrected manually as necessary. To determine the lumbar 
skeletal muscle index (LSMI; cm2/m2), the skeletal muscle area 
at the L3 vertebra was normalized to the square of the patient’s 
height (m2).16,17 
3. Definition of T2DM and sarcopenia 
Diabetes mellitus was identified when patients used insulin 
or oral hypoglycemic agents or had a fasting plasma glucose 
level ≥126 mg/dL.18 Sarcopenia was defined as the lowest LSMI 
quartile in our study participants, corresponding to cutoff 
points of 48.10 cm2/m2 in men and 36.04 cm2/m2 in women.
1,191 Subjects received comprehensive medical health check-up
658 Men
533 Women
323 Subjects with diabetes and muscle mass assessment
227 Men
96 Women
309 Subjects (215 men and 94 women) were finally selected
for the statistical analysis
234 Non-sarcopenic (75.7%)
75 Sarcopenic (24.3%)









Prolonged use of oral steroid >3 months
Fig. 1. Flow of study population 
selection.
CT, computed tomography; HBV, 
hepatitis B virus; HCV, hepatitis C 
virus; HIV, human immunodefi-
ciency virus.
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4. Assessment of liver fibrosis and steatosis
In all participants, the fibrotic burden in the liver was assessed 
using the fibrosis-4 (FIB-4) index and NAFLD fibrosis score (NFS), 
which are simple, noninvasive fibrosis scoring systems.19,20 The 
FIB-4 index was calculated using the following formula:19 (age 
[years])×(aspartate aminotransferase [AST] level [U/L])/(platelet 
count [109/L])×(alanine aminotransferase [ALT] level [U/L])1/2. NFS 
was calculated using the following formula: –1.675+(0.037×age 
[years])+(0.094×BMI [kg/m2])+(1.13×impaired glucose tolerance/
diabetes [yes=1, no=0])+(0.99×AST/ALT ratio)–(0.013×platelet 
count [×109/L])–(0.66×serum albumin [g/dL]).20
Subgroup analysis was performed in patients with available 
transient elastography (TE) evaluation (FibroScan; EchoSens, 
Paris, France). The principles of measuring liver stiffness (LS) and 
controlled attenuation parameter using TE have been described 
previously.21,22 The LS results are expressed in terms of kilopas-
cal, while the controlled attenuation parameter results are given 
in dB/m. To estimate variability, we calculated the ratio of the LS 
interquartile range (IQR) to its median. Only a valid LS of ≥10 kPa, 
a success rate of ≥60%, and a ratio of IQR to median LS of ≤30% 
were deemed reliable. The controlled attenuation parameter was 
considered a valid value only when the LS of the same signal was 
reliable.
5. Statistical analysis
The characteristics of the study subjects were analyzed in 
terms of their sarcopenia status using the Student t-test for 
continuous variables and the chi-square test for categorical 
variables. The association between LSMI and fibrotic burden 
represented using FIB-4 index and NFS values was evaluated 
using simple linear regression analysis and the chi-square test 
after transformation of these variables into quartiles. Multivari-
able logistic regression analysis was applied to determine the in-
dependent association between sarcopenia and other variables. 
Continuous variables were expressed as the mean±standard de-
viation, while categorical variables were given in terms of num-
ber (%). p-values <0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS version 23.0 for 
Windows (IBM Corp., Armonk, NY, USA).










   Age, yr 62.7±10.5 60.9±10.0 68.2±10.2 <0.001
   Female sex 94 (30.4) 76 (32.5) 18 (24.0) 0.165
   Body mass index, kg/m2 25.3±2.9 25.7±2.9 23.8±2.3 <0.001
   Hypertension 222 (71.8) 169 (72.2) 53 (70.7) 0.794
Laboratory parameter
   Fasting glucose, mg/dL 122±37 122±36 122±43 0.933
   Aspartate aminotransferase, IU/L 24.6±10.8 24.9±11.3 23.5±9.2 0.326
   Alanine aminotransferase, IU/L 25.9±14.2 27.0±15.2 22.7±9.7 0.005
   Gamma glutamyl-transpeptidase, IU/L 42±48 45±51 34±37 0.086
   Serum creatinine, mg/dL 0.9±0.6 0.9±0.4 1.0±0.8 0.197
   Platelet count, 109/L 228±58 230±60 222±48 0.284
   Prothrombin time, INR 0.94±0.20 0.93±0.07 0.99±0.39 0.028
   Total cholesterol, mg/dL 179±42 181±42 173±40 0.192
   Triglycerides, mg/dL 142±86 147±92 126±63 0.069
   High-density lipoprotein cholesterol, mg/dL 46±11 46±12 47±11 0.774
   Low-density lipoprotein cholesterol, mg/dL 104±35 105±35 100±35 0.386
   HbA1c, % 6.7±1.1 6.7±1.1 6.8±1.3 0.234
Muscle mass parameter
   L3 skeletal muscle area, cm2 139±34 146±33 117±25 <0.001
   Lumbar skeletal muscle index, cm2/m2 50±10 53±9 41±7 <0.001
Fibrosis parameter
   Fibrosis-4 index 1.46±0.64 1.41±0.63 1.63±0.65 0.009
   Liver stiffness, kPa (n=113) 5.2±3.1 4.9±2.7 (n=93) 6.4±1.0 (n=20) 0.159
Data are presented as mean±SD or number (%).
INR, international normalized ratio; HbA1c, glycosylated hemoglobin.
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RESULTS
1. Subject characteristics
The baseline characteristics of the study population are sum-
marized in Table 1. The mean age of the study population was 
62.7 years, while their mean body mass index (BMI) was 25.3 
kg/m2. Their mean fasting glucose was 122 mg/dL, while their 
mean HbA1c (glycosylated hemoglobin) was 6.7%. Their mean 
total cholesterol, triglyceride, high-density lipoprotein choles-
terol, and low-density lipoprotein cholesterol were 179, 142, 46, 
and 104 mg/dL, respectively. Their mean L3 skeletal muscle area 
was 139 cm2, while their mean LSMI was 50 cm2/m2. The mean 
FIB-4 index and NFS in the entire population were 1.46 and 
–0.587, respectively, and the mean LS value was 5.2 kPa in the 
subgroup whose LS value was available (n=113).
2. Comparison between subjects with sarcopenia and 
those without
Of the study participants, 75 (24.3%) had sarcopenia. Subjects 
with sarcopenia were significantly older than those without 
(mean, 68.2 years vs 60.9 years) (Table 1), and they had signifi-
cantly lower BMI (mean, 23.8 kg/m2 vs 25.7 kg/m2; all p<0.05). 
In addition, subjects with sarcopenia had significantly lower 
ALT levels (mean, 22.7 IU/L vs 27.0 IU/L), as well as significant-
ly prolonged prothrombin time (mean international normalized 
ratio, 0.99 vs 0.93) than those without sarcopenia (all p<0.05), 
Fig. 2. Association between muscle mass and fibrotic burden using the fibrosis-4 (FIB-4) index (A) and NAFLD fibrosis score (NFS) (B). The muscle 
mass showed a strong negative association with fibrotic burden using the FIB-4 index (p=0.023).





























































Fig. 3. Association between muscle mass and fibrotic burden by quartile stratification analysis when fibrotic burden was assessed using fibrosis-4 
(FIB-4) index. (A) Muscle mass showed a strong negative association with fibrotic burden (p=0.003). (B) Sarcopenia patients in the lowest quartile 
of muscle mass showed a strong association with fibrotic burden, with FIB-4 ≥1.45 (p=0.019).
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and they had a significantly lower L3 skeletal muscle area (mean, 
117 cm2 vs 146 cm2), as well as a lower LSMI (41 cm2/m2 vs 53 
cm2/m2; all p<0.05). Subjects with sarcopenia had more fibrotic 
liver than those without (mean FIB-4 index, 1.63 vs 1.41; NFS, 
–0.34 vs –0.66; all p<0.05). Among the subgroup who had 
available LS values, as measured by TE (n=113) (Supplementary 
Table 1), the mean LS value was higher in subjects with sarco-
penia than in those without (6.4 kPa vs 4.9 kPa), although the 
difference was not statistically significant (p=0.159).
3. Association between muscle mass and fibrotic burden
Associations between muscle mass and fibrotic burden us-
ing FIB-4 index and NFS were analyzed using simple linear 
regression analysis. Muscle mass assessed using LSMI showed a 
strong negative association with fibrotic burden assessed using 
FIB-4 index (p=0.023), whereas the association between LSMI 
and NFS was not statistically significant (p=0.398) (Fig. 2).
The LSMI by CT scan showed a strong negative association 
with fibrotic burden by FIB-4 index (Fig. 3). When muscle mass, 
measured using CT, was stratified into quartiles, 77 (24.9%), 78 
(25.2%), 76 (24.6%), and 78 (25.2%) subjects were stratified into 
Q1 (lowest quartile, LSMI range: 25.40 to 42.81 cm2/m2), Q2 (low-
intermediate quartile, LSMI range: 42.90 to 48.96 cm2/m2), Q3 
(high-intermediate quartile, LSMI range: 49.18 to 56.35 cm2/m2), 
and Q4 (highest quartile, LSMI range: 56.44 to 73.95 cm2/m2), 
respectively. Similarly, when fibrotic burden by FIB-4 index was 
stratified by quartile, 77 (24.9%), 77 (24.9%), 78 (25.2%), and 77 
(24.9%) subjects were stratified into Q1 (lowest quartile, FIB-4 
range: 0.44 to 0.99), Q2 (low-intermediate quartile, FIB-4 range: 
0.99 to 1.30), Q3 (high-intermediate quartile, FIB-4 range: 1.30 to 
1.87), and Q4 (highest quartile, FIB-4 range: 1.89 to 4.06), respec-
tively. The quartile stratification of fibrotic burden and muscles 
showed a significantly association (p=0.003). When an FIB-
4 index value of 1.45, the cutoff value for ruling out advanced 
fibrosis, was used, the proportion of patients with FIB-4 ≥1.45 in 
the subgroup with sarcopenia was significantly higher than that 
in the subgroup without sarcopenia (56.0% vs 40.6%; p=0.019).
4. Independent predictors of sarcopenia
Among the measured variables, age, BMI, ALT level, FIB-4 
index, and NFS showed significant correlation with the risk of 
sarcopenia in univariate analysis (all p<0.05) (Table 2). Because 
age and ALT are constituent variables of the FIB-4 index, they 
were not incorporated into the multivariate analysis. Similarly, 
because BMI is a constituent variable of NFS, it was not incor-
porated into the multivariate analysis. However, because gender 
is a significant predictor of sarcopenia, we included gender in 
the multivariate analysis, in spite of statistical insignificance in 
univariate analysis (p=0.167).
When FIB-4 index was used for adjustment, female sex and 
higher BMI were independently associated with a reduced risk 
of sarcopenia after adjustment (odds ratio [OR], 0.388; 95% con-
fidence interval [CI], 0.199 to 0.755; p=0.005 for female sex and 
OR, 0.704; 95% CI, 0.618 to 0.801; p<0.001 for BMI), whereas 
Table 2. Independent Predictors of Sarcopenia
Variable
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age 1.075 (1.045–1.106) <0.001 - -
Female sex 0.657 (0.362–1.192) 0.167 0.388 (0.199–0.755) 0.005
Body mass index, kg/m2 0.743 (0.660–0.838) <0.001 0.704 (0.618–0.801) <0.001
Hypertension 0.927 (0.522–1.644) 0.794 - -
Fasting glucose 1.000 (0.993–1.007) 0.933 - -
Aspartate aminotransferase, IU/L 0.987 (0.961–1.014) 0.328 - -
Alanine aminotransferase, IU/L 0.975 (0.953–0.997) 0.026 - -
Gamma glutamyl-transpeptidase, IU/L 0.993 (0.984–1.001) 0.097 - -
Serum creatinine, mg/dL 1.284 (0.852–1.937) 0.232 - -
Platelet count, 109/L 0.997 (0.993–1.002) 0.283 - -
Prothrombin time, INR 11.488 (0.471–280.000) 0.134 - -
Total cholesterol, mg/dL 0.996 (0.989–1.002) 0.193 - -
Triglycerides, mg/dL 0.997 (0.993–1.000) 0.072 - -
High-density lipoprotein cholesterol, mg/dL 1.003 (0.981–1.026) 0.773 - -
Low-density lipoprotein cholesterol, mg/dL 0.997 (0.989–1.004) 0.385 - -
HbA1c, % 1.139 (0.918–1.412) 0.237 - -
Fibrosis-4 index 2.195 (1.426–3.379) 0.003 1.817 (1.180–2.797) 0.007
OR, odds ratio; CI, confidence interval; INR, international normalized ratio; HbA1c, glycosylated hemoglobin.
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higher FIB-4 index was independently associated with an in-
creased risk of sarcopenia (OR, 1.817; 95% CI, 1.180 to 2.797; 
p=0.007). When age and ALT, the respective variables of FIB-
4 index, were adjusted, older age was independently associated 
with the increased risk of sarcopenia (OR, 1.086; 95% CI, 1.051 
to 1.122; p<0.001), whereas female sex and higher BMI were 
independently associated with a reduced risk of sarcopenia (OR, 
0.280; 95% CI, 0.138 to 0.568; p<0.001 for female sex and OR, 
0.710; 95% CI, 0.620 to 0.814; p<0.001 for BMI) (Supplementary 
Table 2). When NFS was used for adjustment, only higher NFS 
was independently associated with an increased risk of sarcope-
nia (OR, 1.322; 95% CI, 1.028 to 1.698; p=0.029) (Table 2).
In the subgroup with LS values available, female sex (OR, 
0.102; 95% CI, 0.012 to 0.897; p=0.040) and higher BMI (OR, 
0.678; 95% CI, 0.522 to 0.894; p=0.006) were independently 
associated with a reduced risk of sarcopenia after adjustment, 
whereas LS tended to be associated with sarcopenia, with bor-
derline statistical significance (p=0.086) (Supplementary Table 3).
5. Degree of liver fibrosis and sarcopenic status stratified 
by BMI and gender
To investigate the association between the degree of liver fi-
brosis and sarcopenic status without the confounding influences 
of obesity and gender, we stratified the study population using a 
BMI cutoff value of 25 kg/m2 (n=165 [53.4%] with a BMI <25 kg/m2 
and n=144 [46.6%] with a BMI ≥25 kg/m2), as well as gender (men, 
n=215 [69.6%]; women, n=94 [30.4%]) (Fig. 4). 
Among the men, the FIB-4 index of patients with sarcopenia 
(n=57, 26.5%) tended to be higher than that of those with-













































































































Fig. 4. Fibrotic burden was assessed using the fibrosis-4 (FIB-4) index and NAFLD fibrosis score (NFS) according to sarcopenic status after stratifi-
cation according to sex and BMI (<25 and ≥25 kg/m2). When analyzed using FIB-4, sarcopenic subjects had a significantly higher fibrotic burden 
than nonsarcopenic subjects in the subgroups with female sex (A) and BMI <25 kg/m2 (B) (all p<0.05). When analyzed using NFS, sarcopenic sub-
jects had a significantly higher fibrotic burden than nonsarcopenic subjects in subgroups of male sex (C) and a BMI <25 kg/m2 (D) (all p<0.05).
NAFLD, nonalcoholic fatty liver disease; BMI, body mass index.
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reached (mean, 1.59 vs 1.40; p=0.058) (Fig. 4A). However, when 
analyzed using NFS, among the men, the NFS of men with 
sarcopenia (n=57, 26.5%) was significantly higher than that of 
those without (n=158, 73.5%) (mean, –0.31 vs –0.65; p=0.042) 
(Fig. 4C). In addition, among the women, the FIB-4 index of 
patients with sarcopenia (n=18, 19.1%) was significantly higher 
than that of those without (n=76, 80.9%) (mean, 1.77 vs 1.43; 
p=0.038) (Fig. 4A). However, when analyzed using NFS, among 
the women, the NFS was statistically similar between women 
with sarcopenia (n=18, 19.1%) and those without sarcopenia 
(n=76, 80.9%) (mean, –0.42 vs –0.69; p=0.374) (Fig. 4C).
Among the 165 subjects with a BMI of <25 kg/m2, patients 
with sarcopenia (n=54, 32.7%) had significantly higher FIB-4 
index and NFS values than those without (n=111, 67.3%) (mean 
FIB-4, 1.66 vs 1.38; p=0.004 and NFS, –0.42 vs –0.97; p=0.002, 
respectively) (Fig. 4B and D). Among the 144 patients with a 
BMI ≥25 kg/m2, FIB-4 index and NFS were statistically similar 
between patients with sarcopenia (n=123, 85.4%) and those 
without (n=21, 14.6%) (mean FIB-4, 1.55 vs 1.44 and NFS, 
–0.13 vs –0.39, respectively; all p<0.05) (Fig. 4B and D). 
When the subgroup with the LS value available was assessed, 
LS values were statistically similar between patients with sarco-
penia and those without (all p>0.05) (Supplementary Fig. 1). 
DISCUSSION 
In the present study, we found that around one quarter of di-
abetic patients had sarcopenia (24.3%), and that muscle mass, as 
measured by LSMI, was significantly negatively associated with 
fibrotic burden in liver, as measured by FIB-4 index (p=0.003). 
In addition, we found that female sex (OR, 0.388) and higher 
BMI (OR, 0.704) were independently associated with a reduced 
risk of sarcopenia, whereas higher fibrotic burden in liver, as 
reflected by higher FIB-4 index (OR, 1.817), was independently 
associated with an increased risk of sarcopenia in patients with 
diabetes. However, when NFS was used for adjustment, only 
higher NFS was independently associated with an increased 
risk of sarcopenia after adjustment (OR, 1.322). When the study 
population was stratified according to gender, patients with sar-
copenia tended to have higher FIB-4 index and NFS values than 
those without in the male subgroup (mean FIB-4, 1.59 vs 1.40 
and NFS, –0.31 vs –0.65), whereas FIB-4 index was significantly 
higher in patients with sarcopenia in the female subgroup (mean, 
1.77 vs 1.43; p=0.038). When the study population was strati-
fied according to BMI, FIB-4 index and NFS were significantly 
higher in patients with sarcopenia than in those without in the 
subgroup with a BMI <25 kg/m2 (mean FIB-4, 1.66 vs 1.38 and 
NFS, –0.42 vs –0.97). However, the FIB-4 index and NFS were 
statistically similar between patients with and without sarcope-
nia in the subgroup with a BMI ≥25 kg/m2.
Our study had several strengths. Firstly, we measured skeletal 
muscle mass using CT. Several previous studies have shown that 
CT scanning is more accurate than DXA or BIA in the quantita-
tive measurement of skeletal muscle mass.3,23 In addition, CT-
measured values of skeletal muscle mass have been associated 
with qualitative measures of skeletal muscle function, such as 
strength and physical performance;3 the main pitfalls of DXA 
and BIA in this regard are their dependency on assumptions 
regarding the density and hydration fraction of fat-free mass, 
which can be biased in patients with advanced liver disease, 
because they tend to retain water.3,23 Furthermore, to assess 
skeletal muscle mass using DXA or BIA, specific equipment is 
required, whereas CT scanning is readily available in most insti-
tutions.24 Thus, the results of our study might be readily appli-
cable in clinical practice, helping physicians to identify patients 
with sarcopenia who are at risk of liver fibrosis progression and 
provide appropriate medical interventions, such as exercise and 
protein supplements.
Secondly, our study focused on diabetic patients. In chronic 
hepatitis B and hepatitis C virus infections, as well as in NAFLD, 
T2DM has been related to liver fibrosis,25,26 and the prevalence of 
sarcopenia is higher in diabetic patients.27 Several recent stud-
ies have confirmed an independent association between fibrotic 
burden in the liver and sarcopenia in NAFLD and hepatitis B 
virus cohorts.11-14 In these studies, the independent association 
between liver fibrosis and sarcopenia was found to be indepen-
dent of insulin resistance, although few studies have focused on 
patients with diabetes. In the current study, which had quite a 
large sample size (n=309), homogeneous diabetic patients were 
recruited to exclude the influence of T2DM itself on liver fibro-
sis. This may have ensured statistical reliability in this specific 
population. In this regard, a previous study reported the asso-
ciation between liver fibrosis and sarcopenia, as assessed using 
body circumference, in a diabetic cohort. The results showed 
that higher waist-to-calf circumference ratio, which is related 
to sarcopenic obesity, was associated with an increased risk of 
NAFLD and liver fibrosis, independent of insulin resistance.28 
Thirdly, the results of our current study were supported by 
several recent studies,10-14,28,29 which indicated that liver fibrosis 
progression is significantly associated with skeletal muscle loss, 
regardless of various concomitant medical illnesses. Indeed, 
there is likely a significant association between liver fibrosis 
and sarcopenia in patients with NAFLD, although this has not 
yet been confirmed.11 Thus, considering that both fatty liver 
and T2DM involve insulin resistance,30 it is not surprising that 
fibrosis is significantly associated with sarcopenia in diabetic 
patients as well. The mechanism of the independent associa-
tion between the degree of sarcopenia and fibrotic burden in 
the liver was not revealed in the present cross-sectional study. 
However, the underlying mechanisms of sarcopenia in the 
NAFLD and T2DM cohorts may be related to insulin resistance, 
vitamin D deficiency, myostatin, sedentary lifestyle, etc.31 Thus, 
our study again indicated the need for future studies to investi-
gate whether exercise, nutritional supplementation, and medical 
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treatment of sarcopenia can ameliorate liver fibrosis.29,32,33
Fourthly, previous studies have indicated that the preva-
lence of sarcopenia is higher in women than in men,34 perhaps 
because there is a higher prevalence of NAFLD in women.11 
However, in the present study, we found that the association be-
tween liver fibrosis and sarcopenia was consistent regardless of 
gender, although it did show borderline statistical significance 
men (p=0.058). This might indicate that the clinical implications 
of sarcopenia and corresponding liver fibrosis differ between 
genders, and that the difference in liver fibrotic burden between 
patients with sarcopenia and those without is only significant 
in the subgroups with a BMI <25 kg/m2. This might indicate 
that subjects with sarcopenic obesity have a similar risk of liver 
fibrosis progression than those with non-sarcopenic obesity. 
However, because subjects with sarcopenic obesity have poorer 
prognosis than those with non-sarcopenic obesity, including 
poorer physical performance and higher risk of cardiovascular 
disease and metabolic syndrome,6,7,35,36 future studies should 
assess whether long-term liver-related outcomes are similar 
between these groups. In addition, further studies might be 
required to define a new BMI cutoff value that can reveal the 
influence of sarcopenia among subjects with obesity. 
There were also several unresolved issues in the present 
study. Firstly, because this was a cross-sectional study, we could 
not investigate the influence of insulin resistance, anti-diabetic 
medications, or illness duration. In this regard, several previous 
studies have shown that some anti-diabetic drugs can induce 
muscle atrophy,37,38 so further studies are required to resolve 
this issue. Secondly, due to the cross-sectional and retrospec-
tive nature of our study, we could not evaluate the influence of 
sarcopenia on the prognosis of patients with of T2DM or assess 
the longitudinal dynamic association between liver fibrosis pro-
gression and changes in muscle mass during the natural course 
or after therapeutic interventions, such as lifestyle modification, 
exercise, and weight loss. However, based on our results, we 
might cautiously recommend exercise or protein supplements 
when muscle mass falls below cutoff levels. Thirdly, we used 
CT to measure skeletal muscle mass. Although muscle mass 
assessed using CT can also reflect muscle function such as 
muscle strength and physical performance,3 further validation 
studies are required. Fourthly, due to differences in scanning 
thickness depending on the number of channels in varying CT 
scans, areas at the mid L3 level might vary slightly for each 
machine. Fifthly, our study is not free from potential selection 
bias, because only subjects who could afford to pay the cost for 
the comprehensive medical health check-up including CT scans 
were recruited. Fifthly, some results were discordant according 
to the use of FIB-4 index or NFS, probably due to the differ-
ent constituent variables and overall small sample size. Further 
validation study is required to resolve this issue. Lastly, in the 
subgroup analysis of patients with available TE results, the asso-
ciation between fibrotic burden, expressed as LS and sarcopenia, 
was not statistically significant, probably due to the insufficient 
sample size. Because TE can accurately assess fibrotic burden in 
the liver, further studies using TE are warranted. 
In conclusion, the present retrospective study found that 
sarcopenia is independently associated with fibrotic burden in 
patients with T2DM. Further well-designed, prospective, longi-
tudinal studies are warranted to elucidate the complex relation-
ship between sarcopenia and liver fibrosis progression.
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